Prevenar and Pneumo23 — Competitive Intelligence Brief

Prevenar and Pneumo23 (Prevenar and Pneumo23) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vaccine. Area: Immunology / Infectious Disease.

phase 3 Vaccine Streptococcus pneumoniae polysaccharide antigens Immunology / Infectious Disease Biologic

Target snapshot

Prevenar and Pneumo23 (Prevenar and Pneumo23) — Hospital Universitari Son Dureta. Prevenar and Pneumo23 are pneumococcal conjugate and polysaccharide vaccines that stimulate the immune system to produce antibodies against Streptococcus pneumoniae.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Prevenar and Pneumo23 TARGET	Prevenar and Pneumo23	Hospital Universitari Son Dureta	phase 3	Vaccine	Streptococcus pneumoniae polysaccharide antigens
GSK1024850A (SynflorixTM)	GSK1024850A (SynflorixTM)	GlaxoSmithKline	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
GSK Biologicals' Synflorix™	GSK Biologicals' Synflorix™	GlaxoSmithKline	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 5, 6B, 7F, 9V, 14, 19F, 19A, 23F, and others)
GSK1024850A (Synflorix)	GSK1024850A (Synflorix)	GlaxoSmithKline	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
SynflorixTM	SynflorixTM	GlaxoSmithKline	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
Synflorix™ vaccine	Synflorix™ vaccine	GlaxoSmithKline	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F)
Prevnar (PCV7)	Prevnar (PCV7)	University of Minnesota	phase 3	Pneumococcal conjugate vaccine	Streptococcus pneumoniae polysaccharide antigens (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 12 drugs in this class
3. Pfizer · 6 drugs in this class
4. International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
5. Henogen · 3 drugs in this class
6. Pfizer Inc. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Jiangsu Province Centers for Disease Control and Prevention · 2 drugs in this class
9. BioNTech · 2 drugs in this class
10. Merck Sharp & Dohme LLC · 2 drugs in this class